Fig. 1.

Correlation between WBP2 and doxorubicin resistance in ER-positive breast cancer cells. a Protein levels of WBP2 in normal breast epithelial cells (MCF10A) and breast cancer cells (MCF-7, MCF-7/ADR, SKBR3, MDA-MB-231, HS578t and BT-549). b Relative expression of WBP2 mRNA in MCF-7 and MCF-7/ADR cells. c Protein levels of WBP2 in ER-negative breast cancer cells (MDA-MB-231 and MDA-MB-231/ADR) and ER-positive breast cancer cells (MCF-7 and MCF-7/DDP). Differential protein expression (d) and mRNA expression (e) of WBP2 in MCF-7 and BT474 cells treated with DMSO or 0.5 μM doxorubicin for 24 h. f Differential protein expression of WBP2 in MCF-7 and BT474 cells treated with 0.2 μM doxorubicin for 0, 24, 48 and 72 h. Dox indicates doxorubicin. **P < 0.01